- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: IFN-alpha-2 | interferon alpha-2 | Roferon A®
IFN-α2 is an approved drug (FDA (1989))
Compound class: Endogenous peptide in human, mouse or rat
Comment: IFN-α2 is a type I IFN. The sequence of the recombinant peptide used clinically and known as interferon alfa-2a, is identical to that of human IFN-α2. Interferon alfa-2a has anti-viral, immunomodulatory and antineoplastic actions.
Pegylated IFN alfa 2a is on the World Health Organization's List of Essential Medicines. Click here to access the pdf version of the WHO's 21st Essential Medicines list (2019).
Orphan Products Designation Search Page.
Accessed on 04/07/2016. Modified on 04/07/2016. US Food and Drugs Administration- Orphan Products Designation Search Page, http://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm?StartRow=1&EndRow=25
Orphan Products Designation Search Page (Natural human lymphoblastoid interferon-alpha).
Accessed on 04/07/2016. Modified on 04/07/2016. US Food and Drug Administration- Orphan Drug Designations and Approvals, http://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm
3. Maurer B, Bosanac I, Shia S, Kwong M, Corpuz R, Vandlen R, Schmidt K, Eigenbrot C. (2015)
Structural basis of the broadly neutralizing anti-interferon-α antibody rontalizumab.
Protein Sci., 24 (9): 1440-50. [PMID:26099203]
4. Witte A, Williams D, Cardarelli JM, King D, Passmore D. (2010)
Anti-interferon Alpha Antibodies.
Patent number: US7741449. Assignee: Medarex, Inc.. Priority date: 10/12/2003. Publication date: 22/06/2010.